Sasquatch secret documents reveal the manufacturing of mosquitos is little different than the manufacturing of a virus.
Before heading out for a visit with Tecumseh, I am triggered by an overwhelming urge to take a little trek back into the far reaches of the Internet world, into the dark well of bio-engineering, or as I call it, The God Syndrome. I have learned that these sudden urges are not to be ignored per Bigfoot Parchment number three: nothing is by coincidence.
Manmade creatures are becoming common place in University labs across the world. Science has seemingly lost all semblance of a conscience, where its blind followers do not believe in the spiritual nature and source of life, but instead they believe life comes from viruses and genes. This disconnect from the true source of life allows them to hide behind all manner of justifications for their virus and gene monkeying in order to create their Frankenstein bugs.
I have had my attention directed upon a company called Oxitec, an offshoot of Oxford University in England. Financially wealthy from their benefactors and big corporations, they are quietly going about the business of altering the genes of insects under the guise of pest control. It all sounds innocent and helpful to the eyes and ears of our troubled world where science has elevated itself to the venerated position of a demigod. The spiritually advanced Sasquatch would beg to differ. That is why there has been an all out government spin to portray them as apes instead of the intelligent and powerful beings they actually are.
When the Sasquatch know and I say the Covid 19 virus was created in a lab by off the rails men in white coats, I say it with certainty. It is not a Conspiracy Theory, it is Conspiracy Fact based, even if it was a so called “accident.” As I stated earlier, I fully subscribe to the Sasquatch Parchment precept that: nothing happens by coincidence.
Here is a prime example of the truth straight off the Internet. This is not made up. This goes on twenty-four seven all across the globe. It manifests in many forms backed by huge sums of money that should be used for real life-changing improvements, instead of turning bugs into biological nuclear bombs.
The company called Oxitec states, in its own words, not mine: “Our insects contain a self-limiting gene, and when this gene is passed on to their offspring, offspring do not survive to adulthood, resulting in a reduction in the pest insect population.
We call this method “self-limiting” because the released insects and the self-limiting gene that they pass on are designed to die and disappear from the environment.
We release males, because it is the female insects that are directly responsible for spreading disease or producing larvae that damage crops. Our males have one job: to find wild females where they live and mate with them.
This method can be applied to all kinds of insect pests, from the mosquitoes that transmit such diseases as dengue and Zika, to moth caterpillars that destroy maize fields. We’ve created our insects using precise genetic engineering tools. They are just like wild insects, except we’ve inserted two additional genes.
The self-limiting gene prevents offspring of our released male insect from surviving to adulthood, and a fluorescent marker gene produces a protein throughout the body of the insects, which glows when exposed to a specific colour of light. This helps us to track our insects in the wild.”
Sounds great doesn’t it? You are supposed to be impressed with such scientific bluster portrayed as miracles by those with impressive scientific credentials. I know what you are thinking, but bear with me a wee bit longer.
Let’s once again use Oxitec’s own words, not mine.
“The self-limiting gene is at the heart of our method of insect control. When our male insects are released and reproduce with wild females, all of their offspring inherit a copy of this gene. The self-limiting gene disrupts the proper functioning of the insects’ cells by over-producing a protein in them, interfering with the cells’ ability to produce other essential proteins needed for development. So by disrupting the insect’s normal development, the gene prevents it from surviving to adulthood.
Since the self-limiting gene works by using the insect’s own biology against itself, our control method provides a solution that only affects that particular species of pest without introducing harmful toxins.
We have also designed our insects so that we can turn off the self-limiting gene with an antidote called tetracycline. This allows us to breed our insects at a large scale without the need for any additional genetic engineering. Our 2nd Generation Friendly™ Aedes aegypti mosquitoes, for example, were engineered in 2013, and we have been breeding the strain from those original mosquitoes ever since!
You may even think that just sounds wonderful! What’s wrong with me, you say? These guys are genius’.
What you probably missed, buried in all the bluster is the Covid 19 connection in the third sentence: “The self-limiting gene disrupts the proper functioning of the insects’ cells by over-producing a protein in them, interfering with the cells’ ability to produce other essential proteins needed for development.” Sound familiar? It should. The spike proteins produced by the Covid 19 virus do the exact same thing in humans. These protein reactions are not native to natural life, they were manmade in a laboratory. In the case of Covid 19, it was developed and funded by grant money and partnerships between Universities and Corporations. No joke folks. This is fact. Check out the Covid 19 connection between Oxitec and BBSRC. Modern humanity has unwittingly become the proverbial rat in the psychiatric maze. They are now ringing the bell for you to run down and get your vaccination against their very own man-made Frankenstein virus.
If you still have doubts, reread the next paragraph of Oxitec’s dissertation. “Since the self-limiting gene works by using the insect’s own biology against itself, our control method provides a solution that only affects that particular species of pest without introducing harmful toxins.” This again should ring a bell. That is the exact killing mechanism that has put Covid patients on respirators and in their graves. The immune system attacks itself with the over production of the protein introduced by the self-limiting gene so touted by these genius’s.
Here are Oxitec’s partners and funders. Again, taken off Oxitec’s Website: University of Oxford, GBIT, Piracicaba, BBSRC bioscience of the future, Bill and Melinda Gates Foundation.
If you think these so called Scientists have control over their experiments exported from the lab into the natural world, I have news for you, THEY DON’T! You think Gates money is squeaky clean and legitimate? Hah! If you believe these crackpots and CDC’s propaganda, then I know your relationship with the Sasquatch is about as deep as a back road mud puddle. Good luck! Karma is the life of hard knocks.
Now I have work to do. Tecumseh and Demarcus are waiting.
Sasquatch secret documents reveal that a half million dollar grant has been awarded to the University of California at Riverside to research the virtual poisoning of the world's future food sources. This kind of lab-to-field implementation would be a nuclear threat to our non GMO seed bank. Pay attention folks! Don't let the intellectual language fool you. Forget the buzzwords and the political attacks from those calling us conspiracy theorists. We aren't theorists at all. We follow the money and the data, they clearly speak for themselves.
CHECK OUT THESE SASQUATCH SECRET DOCUMENTS RECENTLY SHOWN TO ME BY MY FRIENDS FROM THE OTHER SIDE, THE BIG CREEK SASQUATCH AND THEIR HUMAN HELPERS.
THIS IS WHAT THE YOUNG SASQUATCH OF CROSS OVER ARE TAPPING INTO FROM THE 5G MICROWAVES THAT ARE SEEPING INTO THEIR CROSS OVER WORLD.
THIS IS THE WORLD OF WHICH THEIR CONCERNED VISITOR, TED KACZYNSKI, WAS TRYING TO ALERT HUMANITY TO.
SPIRITLESS INSANITY HAS TAKEN OVER THE ASYLUM AND THE BIGFEET ARE GETTING AGITATED. THEY HAVE CAUTIONED ME THAT THE TIME IS RAPIDLY APPROACHING WHEN THE DRUMS FOR THE BIGFOOT MARCH WILL SOUND.
LOOK BEYOND THE SURFACE OF THESE MATRIX DOCUMENTS AS TO WHAT IS LURKING BEHIND THE DOORS OF HUGE CORPORATIONS AND HIGHER EDUCATION. IF THIS DOESN'T WAKE YOU UP MORE THAN A BELLIGERENT BIGFOOT ENCOUNTER, THEN NOTHING WILL.
Award Abstract # 2134535
FMSG: Bio: Rapid Biomanufacturing of mRNA Vaccines in Plant Chloroplasts
CBET Div Of Chem, Bioeng, Env, & Transp Sys Awardee:REGENTS OF THE UNIVERSITY OF CALIFORNIA AT RIVERSIDE Initial Amendment Date: August 10, 2021 Latest Amendment Date: August 10, 2021 Award Number: 2134535 Award Instrument: Standard Grant Program Manager: Steve Zehnder firstname.lastname@example.org (703)292-7014 CBET Div Of Chem, Bioeng, Env, & Transp Sys ENG Directorate For Engineering Start Date: January 1, 2022 End Date: December 31, 2023 (Estimated) Total Intended Award Amount: $500,000.00 Total Awarded Amount to Date: $500,000.00 Funds Obligated to Date: FY 2021 = $500,000.00 History of Investigator: Juan Giraldo (Principal Investigator)
email@example.com (617)909-6315 Gregory Lowry (Co-Principal Investigator) Nicole Steinmetz (Co-Principal Investigator) Awardee Sponsored Research Office: University of California-Riverside Research & Economic Development RIVERSIDE CA US 92521-0217 (951)827-5535 Sponsor Congressional District: 41 Primary Place of Performance: University of California-Riverside Research & Economic Development RIVERSIDE CA US 92507-4633 Primary Place of Performance Congressional District: 41 DUNS ID: 627797426 Parent DUNS ID: 071549000 NSF Program(s): FM-Future Manufacturing Primary Program Source: 040100 NSF RESEARCH & RELATED ACTIVIT Program Reference Code(s): 068Z Program Element Code(s): 142Y Award Agency Code: 4900 Fund Agency Code: 4900 CFDA Number(s): 47.041
This project aims to enable rapid manufacturing of oral vaccines against viruses in plants without the need of specialized equipment or skills. Current vaccine manufacturing technologies need expensive laboratory facilities and cold-chain delivery systems that result in slow and unequal access of vaccines to people. This study combines ideas and approaches from the engineering of particles, chloroplast genetics, and plant molecular farming, to turn chloroplasts of edible plant leaves like spinach or lettuce into biomanufacturing devices for vaccine production. The project will increase public awareness of how engineered particles can be used to turn plants into a biomanufacturing technology through science outreach events and publicly available videos. It will also provide unique opportunities for postdoctoral researchers and students to grow beyond their disciplinary background and practice team science and technology development. A new college level course on engineering plants with engineered particles will incorporate these plant biomanufacturing findings into its curriculum. Partnerships with industry will inform the design, applicability, and cost-effectiveness of plant biomanufacturing technologies, and provide valuable networking and education opportunities for students and postdocs. Plant biomanufacturing hybrid meetings will promote integration of key stakeholders from academia and industry. Together, these approaches will train a future biomanufacturing workforce prepared to develop and apply fundamental knowledge and skills to solve major health, environmental, and sustainability problems.
This project aims to develop tools that allow rapid synthesis and universal access of oral mRNA vaccines manufactured in situ by plant chloroplasts. There is an untapped potential for utilizing chloroplasts as ubiquitous solar powered molecular factories for personalized biomanufacturing devices enabled by emergent nanotechnology-based tools. Chloroplasts are biomanufacturing organelles with a prokaryotic-like genome, their own transcription and translation machinery, but lack gene silencing mechanisms. This system enables high expression of transgenes in plants for rapid, tunable, and scalable manufacturing of mRNA vaccines anywhere plants grow. Despite great strides made in biotechnology, chloroplast genetic engineering remains limited to a few plant species, impairing the use of plants as widely accessible biomanufacturing devices. The main method for the introduction of recombinant DNA to chloroplasts in plants is costly, and requires materials and equipment that are only accessible to specialized lab facilities. Existing methods are also destructive, inefficient, and unable to target genes into chloroplasts. Novel technologies are also needed for facile encapsulation and retrieval of mRNA vaccines synthesized in plants in non-laboratory conditions. The study will investigate biocompatible and degradable high aspect ratio nanomaterials with controllable dimensions, tunable surface charge and chemistry as plasmid DNA delivery vehicles for turning edible plants into mRNA vaccine biomanufacturing devices. Orthogonally, it will determine if mRNA synthesis in chloroplasts and encapsulation in the organelle double lipid envelopes provide a layer of protection from degradation in the environment. Partnerships with industry will inform the design, applicability, and cost-effectiveness of plant biomanufacturing technologies, and provide valuable networking and education opportunities for students and postdocs. Students from UC Riverside, a minority-serving institution, will be recruited to participate in the project. A new course on plant nanobiotechnology at UC Riverside will incorporate the findings of this project on plant biomanufacturing into its curriculum. Nanobiotechnology-based approaches have the potential to democratize the use of plant chloroplasts for personalized biomolecule manufacturing and revolutionize the treatment of human and animal disease.
This Future Manufacturing award is supported by the Division of Chemical, Bioengineering, Environmental, and Transport Systems and the Division of Chemistry.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Vaccines in your salad? Scientists growing medicine-filled plants to replace injections
StudyFinds.org via Nexstar Media Wire Sep 19, 2021 / 08:35 PM CDT
Posted: Sep 19, 2021 / 08:35 PM CDT / Updated:
(StudyFinds.org) – Vaccinations can be a controversial subject for many people, especially when it comes to injections. So what if you could replace your next shot with a salad instead? Researchers at the University of California-Riverside are working on a way to grow edible plants that carry the same medication as an mRNA vaccine.
The COVID-19 vaccine is one of the many inoculations which use messenger RNA (mRNA) technology to defeat viruses. They work by teaching cells from the immune system to recognize and attack a certain infectious disease. Unfortunately, mRNA vaccines have to stay in cold storage until use or they lose stability. The UC-Riverside team says if they’re successful, the public could eat plant-based mRNA vaccines — which could also survive at room temperature.
Thanks to a $500,000 grant from the National Science Foundation, researchers are now looking to accomplish three goals. First, the team will try to successfully deliver DNA containing mRNA vaccines into plant cells, where they can replicate. Next, the study authors want to show that plants can actually produce enough mRNA to replace a traditional injection. Finally, the team will need to determine the right dosage people will need to eat to properly replace vaccinations.
“Ideally, a single plant would produce enough mRNA to vaccinate a single person,” says Juan Pablo Giraldo, an associate professor in UCR’s Department of Botany and Plant Sciences, in a university release.
“We are testing this approach with spinach and lettuce and have long-term goals of people growing it in their own gardens,” Giraldo adds. “Farmers could also eventually grow entire fields of it.”
Plants are capable of growing more vaccines
Giraldo and a team of scientists from UC-San Diego and Carnegie Mellon University say the key to making edible vaccines are chloroplasts. These are small organs inside plant cells which help convert sunlight into energy.
“They’re tiny, solar-powered factories that produce sugar and other molecules which allow the plant to grow,” Giraldo explains. “They’re also an untapped source for making desirable molecules.”
Previous studies have shown that it’s possible for chloroplasts to express genes that are not a natural part of that plant. Giraldo’s team accomplished this by sending genetic material inside of a protective casing into plant cells.
In the new study, Giraldo teamed with UC-San Diego’s Professor Nicole Steinmetz to use nanotechnology to deliver more genetic material into chloroplasts.
“Our idea is to repurpose naturally occurring nanoparticles, namely plant viruses, for gene delivery to plants,” Steinmetz says. “Some engineering goes into this to make the nanoparticles go to the chloroplasts and also to render them non-infectious toward the plants.”
“One of the reasons I started working in nanotechnology was so I could apply it to plants and create new technology solutions. Not just for food, but for high-value products as well, like pharmaceuticals,” Giraldo adds.
Sasquatch Secret Documents reveals the true timeline source of COVID and the COVID jab. This is a document compiled and put forth by Dr. David Martin. Taken from the Internet on November 21, 2021. The link to the source of this document is www.redvoicemedia.com
September 8-16, 2020
A Timeline of Selected Federal Funding for SARS Coronavirus
Over the past two decades, M·CAM has been monitoring possible violations of the 1925 Protocol for the Prohibition of the Use in War of Asphyxiating, Poisonous, or other Gases, and of Bacteriological Methods of Warfare (the Geneva Protocol) 1972 Convention on the Prohibition of the Development, Production, and Stockpiling of Bacteriological and Toxin Weapons and Their Destruction (the BTWC). In its 2003-2004 Global Technology Assessment: Vector Weaponization we identified M·CAM highlighted China’s growing involvement in Polymerase Chain Reaction (PCR) technology with respect to joining the world stage in chimeric construction of viral vectors. Since that time, on a weekly basis, we have monitored the development of research and commercial efforts in this field, including, but not limited to, the research synergies forming between the United States Centers for Disease Control and Prevention (CDC), the National Institutes for Allergies and Infectious Diseases (NIAID), the University of North Carolina at Chapel Hill, Harvard University, Emory University, Vanderbilt University, Tsinghua University, University of Pennsylvania, and their commercial affiliations.
We noted the unusual patent prosecution efforts of the CDC, when on April 25, 2003 they sought to patent the SARS coronavirus that had reportedly transferred to humans during the 2002-2003 SARS outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This legality did not deter CDC in their efforts. Their application, updated in 2007, ultimately issued as U.S. Patent 7,776,521 and constrained anyone not licensed by their patent from developing tests or kits to measure SARS coronavirus in humans. Work associated with this virus by their select collaborators included considerable amounts of chimeric engineering, gain-of-function studies, viral characterization, detection, treatment (both vaccine and therapeutic intervention), and weaponization inquiries.
We noted that gain-of-function specialist, Dr. Ralph Baric, was both the recipient of millions of dollars of U.S. research grants from several federal agencies but also sat on the World Health Organization’s International Committee on Taxonomy of Viruses (ICTV) and the Coronaviridae Study Group (CSG). In this capacity, he was both responsible for determining “novelty” of clades of virus species but directly benefitted from determining declarations of novelty in the form of new research funding authorizations and associated patenting and commercial collaboration. Together with CDC, NIAID, WHO, academic and commercial parties (including Johnson & Johnson; Sanofi and their several coronavirus patent holding biotech companies; Moderna; Ridgeback; Gilead; Sherlock Biosciences; and, others), a powerful group of interests constituted what we would suggest are “interlocking directorates” under U.S. anti-trust laws.
These entities also were affiliated with the WHO’s Global Preparedness Monitoring Board (GPMB) whose members were instrumental in the Open Philanthropy-funded global coronavirus pandemic “desk-top” exercise EVENT 201 in October 2019. This event, funded by the principal investor in Sherlock Biosciences and linking interlocking funding partner, the Bill and Melinda Gates Foundation into the GPMB mandate for a respiratory disease global preparedness exercise to be completed by September 2020 alerted us to anticipate an “epidemic” scenario. We expected to see such a scenario emerge from Wuhan or Guangdong China, northern Italy, Seattle, New York or a combination thereof, as Dr. Zhengli Shi and Dr. Baric’s work on zoonotic transmission of coronavirus identified overlapping mutations in coronavirus in bat populations located in these areas.
Coronavirus Anti-trust Foundations
Dr. Anthony Fauci appointed Director of the NIAID
NIAID Grant AI 23946 leading to patent U.S. 7,279,327 “Methods for Producing Recombinant Coronavirus” Filed 2002 and issued 2007 https://patents.google.com/patent/US7279327B2/ru
This is the first documented commerce association between Dr. Anthony Fauci, NIAID and Dr. Ralph Baric’s recombinant coronavirus enterprise and constitutes the origin of the alleged criminal conspiracy. 15 USC §1-3
The paper first published from the NIAID grant is https://europepmc.org/ backend/ptpmcrender.fcgi?accid=PMC7109931&blobtype=pdf
Pfizer files U.S. Patent 6,372,224 on a vaccine for the S-protein on coronavirus November 14, 2000 which was abandoned April 2010 making it public domain.
Work focused on CoV association with cardiomyopathy (see above)
Early reference to the “emergence” of CoV as a respiratory pathogen in https://link.springer.com/content/pdf/10.1007%2F978-1-4615-1899-0_91.pdf
Ralph Baric AI23946 and GM63228 from the National Institutes of Health actively working recombinant CoV. NIAID and Baric monopolize and conspire to monopolize recombinant coronavirus by entering into a contract using NIH funds for the purpose of restraining trade on coronavirus. 15 USC §1-3
National Institute of Health, Allergy and Infectious diseases. “Reverse Genetics with a Coronavirus Infectious cDNA Construct.” 4/1/2001-3/31/005 $1.0 million total costs/yr. RS Baric, PI
Asia CoV SARS outbreak
April 25, 2003 CDC Patent filed and ultimately becomes US7,220,852 (the patent on the RNA sequence) and 7,776,521 (the patent on the testing methodology. These patents give the U.S. Department of Health and Human Services the ability to control the commercial exploitation of SARS coronavirus.
With their patent filing, CDC enters the conspiracy to restrain interstate trade. The ‘852 patent application was rejected as unpatentable but was allowed in 2007 after having the rejection appealed and overturned provided that the CDC “inventors” acknowledged that they provided an enabling disclosure that placed the genome of SARS coronavirus in the public domain prior to filing their patent application. 15 USC §1-3
Dr. Anthony Fauci appointed to the Bill and Melinda Gates Foundation’s Global Grand Challenges Scientific Advisory Board (served through 2010).
In violation of 15 USC §19, Dr. Fauci has an interlocking directorate violation as NIAID, NIH, and World Health Organization all share common commercial activities.
April 28, 2003 Sequoia Pharmaceuticals $953K for pathogen response and patent US7,151,163 https://www.sbir.gov/node/305319
July 21, 2003 Ralph Baric’s team (using AI23946 and GM63228) file U.S. Patent 7,618,802 which issued on November 17, 2009. https:// patents.google.com/patent/US7618802B2
Dana Farber Cancer Institute files U.S. Patent 7,750,123 on a monoclonal antibody to neutralize SARS CoV. This research is supported by several NIH grants including National Institutes of Health Grants A128785, A148436, and A1053822.
January 6, 2004 – SARS and Bioterrorism linked at Bioterrorism and Emerging Infectious Diseases: antimicrobials, therapeutics and immune modulators. https://tks.keystonesymposia.org/index.cfm? e=web.meeting.program&meetingid=706
At this conference, the term “The New Normal” was introduced by Merck
FAUCI AND BARIC start making money!!! National Institutes of Health, Allergy and Infectious Diseases. SARS Reverse Genetics. AI059136-01. $1.7 million total costs, RS Baric, PI. 10% effort. 4/1/04- 3/31/09. The project develops a SARS-CoV full length infectious cDNA, the development of SARS-CoV replicon particles expressing heterologous genes, and seeks to adapt SARS-CoV to mice, producing a pathogenic mouse model for SARS-CoV infection.
National Institutes of Health, Allergy and Infectious Diseases. R01. Remodeling the SARS Coronavirus Genome Regulatory Network. RS Baric, PI 10% effort. 7/1/04-6/30/09. $2.1 million
November 22, 2004 University of Hong Kong patents SARS associated spike protein on CoV and pursues patent US7,491,489
DARPA gets in on the game Synthetic Coronaviruses. Biohacking: Biological Warfare Enabling Technologies, June 2005. Washington, DC. DARPA/MITRE sponsored event. Invited Speaker
Grab timeline from https://www.youtube.com/watch?v=rO_EeYB0i0U and https://www.davidmartin.world/wp-content/uploads/ 2020/04/20APRBotWslides.pdf
Biodefense Grant U54 AI057157 commences with $10,189,682 to UNC Chapel Hill https://taggs.hhs.gov/Detail/AwardDetail? arg_awardNum=U54AI057157&arg_ProgOfficeCode=104
This is when the colluding parties commence market allocation by providing “non-competitive” grants from NIAID to Dr. Baric’s lab at the same time as Dr. Baric in violation of 15 USC §8.
Biodefense Grant U54 AI057157 continues with $5,448,656 to UNC Chapel Hill (non-competitive grant from NIAID)
Violation of 15 USC §8.
Biodefense Grant U54 AI057157 continues with $8,747,142 to UNC Chapel Hill (non-competitive grant from NIAID)
Violation of 15 USC §8.
Patent issuance for SARS coronavirus patents peak post the Asia outbreak at 391 issued patents.
August 6, 2010, Moderna (prior to its establishment) files U.S. Patent 9,447,164 which attracted the investment of (and “inventorship” for) venture capitalists at Flagship Ventures. This patent grew out of the work of Dr. Jason P. Schrum of Harvard Medical School supported by National Science Foundation Grant #0434507. While the application claims priority to August 2010, the application didn’t get finalized until October, 2015. On November 4, 2015, the USPTO issued a non-final rejection on this original patent rejecting all claims. https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507 with reference to the grant funding in https://molbio.mgh.harvard.edu/ szostakweb/publications/Szostak_pdfs/Schrum_et_al_JACS_2009.pdf
Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February taking with it all of its SARS technology.
Biodefense Grant U54 AI057157 continues with $7,344,820 to UNC Chapel Hill (non-competitive grant from NIAID)
Violation of 15 USC §8.
MERS isolated in Egypt
Biodefense Grant U54 AI057157 continues with $7,627,657 to UNC Chapel Hill (non-competitive grant from NIAID)
Violation of 15 USC §8.
Biodefense Grant U54 AI057157 continues with $7,226,237 to UNC Chapel Hill (non-competitive grant from NIAID)
Violation of 15 USC §8.
Dr. Richard Whitely, member of the Board of Directors of Gilead Sciences (the beneficial licensee of Dr. Baric’s compound for the treatment of coronavirus – Remdesivir), Dr. Baric, and NIAID form the Center for Translational Research. Four university research formed the Centers of Excellence for Translational Research, a program focused on “countering threats from emerging and re-emerging infectious diseases.” The five year grant of $79 million was divided with $37.5 million going to Whitley’s Antiviral Drug Discovery and Development Center at UAB with the balanced divided among Columbia University, Vanderbilt University and the University of North Carolina Chapel Hill. According to Whitely, “When I built the NIAID grant, I decided an important component would be to have a relationship with a pharmaceutical company that could help us develop the drugs that we discovered. I made Gilead Sciences our pharmaceutical colleague in a public-private partnership. At the time, they were screening for drugs to treat respiratory syncytial virus, and the drug that came up as active was remdesivir. They were screening the drug against many viruses as well, including Ebola and coronaviruses. I suggested they give it to us so we could study it in our coronavirus project that was led by Mark Denison at Vanderbilt University and Ralph Baric at the University of North Carolina.”
“AD3C provided data from the Denison and Baric laboratories to Gilead, and that led to clinical investigations.” Remdesivir, initially designed to treat MERS was suggested to be effective in treating SARS. Whitley stated that he was concerned that both MERS and SARS “not only could come back, but be imported into the U.S.”
Violation of 15 USC §1-3, 8, 19.
April 23, 2014, Moderna files patent on nucleic acid vaccine with Patents US9872900 and US10022435
Moderna signs a vaccine development agreement with NIAID and executes it with the lead on the mRNA-1273 lead developer and inventor Guiseppe Ciaramella. https://www.documentcloud.org/documents/ 6935295-NIH-Moderna-Confidential-Agreements.html 2016
NIH through Scripps Institute and Dartmouth College file patent application WO 2018081318A1 “Prefusion Coronavirus Spike Proteins and their Use” disclosing mRNA technology that overlaps (and is used in tandem with) Moderna’s technology. https://patents.google.com/ patent/WO2018081318A1/en Lead Inventor Barney Scott Graham was well known to Moderna as he’s the person at NIH that Moderna “e-mailed” to get the sequence for SARS CoV-2 according to Moderna’s report here (“In January 2020, once it was discovered that the infection in Wuhan was caused by a novel coronavirus, Bancel quickly emailed Dr. Barney Graham, deputy director of the Vaccine Research Center at the National Institutes of Health, asking him to send the genetic sequence for the virus.”) https://www.wsws.org/en/articles/2020/05/26/vacc-m26.html In addition, co-inventor Jason McLellan worked with Graham on a vaccine patent jointly owned with the Chinese government filed in Australia in 2013 https://patents.google.com/patent/AU2014231357A1/ en?inventor=Jason+MCLELLAN.
August – Sanofi buys Protein Science Corp with considerable SARS patent holdings
June – Sanofi buys Ablynx with considerable SARS patent holdings
March, https://wyss.harvard.edu/news/sherlock-biosciences-licenses-wyss-technologyto-create-affordable-molecular-diagnostics/ funded by Open Philanthropy
September – Fauci and Dr. Chris Elias sit on the Global Preparedness Monitoring Board for the WHO stipulating the need to have a global exercise on the accidental or intentional release of a respiratory pathogen by September 2020. Violation of 15 USC § 19
February - Fauci, Baric, and others lament the absence of funding for coronavirus research and highlight the need to have the public see the gravity of their commercial interest.
“Scientists who have applied for funding to study coronaviruses say that they feel more pressure to explain why their research is relevant after an outbreak has ended. Those in the field knew that there was much more to be gleaned about the coronaviruses that already circulate in humans — and that a new coronavirus could start making people sick at any time.” https://www.statnews.com/2020/02/10/fluctuating-funding-and-flagging-interesthurt-coronavirus-research/
This statement was misleading as Dr. Baric’s lab had received million of dollars of non-competitive awards from NIAID without the requirement to “apply” for such funds.
February – Baric sits on the WHO International Committee on Taxonomy of Viruses allowing him to declare “novel” the virus his lab participated in isolating in Violation of 15 USC § 19.
Over 5000 patents and patent applications have included reference to SARS Coronavirus dating back to priority dates of 1998.
On July 23, 2020, the Patent Trial and Appeal Board of the United States Patent and Trademark Office rejected Moderna’s efforts to invalidate U.S. Patent 8,058,069. This patent, owned by Arbutus Biopharma Corp (principally owned by Roivant Science Ltd), covers the lipid nanoparticle (LNP) required to deliver an mRNA vaccine. Some of the core technology was based on work originally done at the University of British Columbia and was first licensed in 1998.
mRNA-1273 – the experimental vaccine developed by Moderna for COVID-19 – uses the LNP technology that Moderna thought it had licensed from Acuitas Therapeutics Inc., a firm developed by a former principal of Arbutus’ prior company Tekmira. That license did not authorize Moderna to use the technology for the COVID-19 vaccine.
M·CAM and Knowledge Ecology International have independently confirmed that Moderna has violated U.S. law in failing to disclose the U.S. government’s funding interest in their patents and patent applications. While this negligence impacts all of Moderna’s over 130 granted U.S. patents, it is particularly problematic for U.S. Patent 10,702,600 (‘600) which is the patent relating to, “a messenger ribonucleic acid (mRNA) comprising an open reading frame encoding a betacoronavirus (BetaCoV) S protein or S protein subunit formulated in a lipid nanoparticle.” The specific claims addressing the pivot to the SARS Coronavirus were patented on March 28, 2019 – 9 months before the SARS CoV-2 outbreak! Both the patent and the DARPA funding for the technology were disclosed in scientific publication (New England Journal of Medicine) but the government funds were not acknowledged in the patent.
In 2013, the Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program awarded grant funding to Moderna Therapeutics for the development of a new type of vaccine based on messenger RNA. The initial DARPA grant was W911NF-13-1-0417. The company used that technology to develop its COVID-19 vaccine, currently undergoing Phase I clinical trials in conjunction with NIH (https:// crsreports.congress.gov/product/pdf/IN/IN11446).
Under the Federal Acquisition Regulation (FAR) rules, contractor to the Federal Government must provide information regarding intellectual property infringement issues as part of their contract. Under FAR §27.201-1(c) and (d), the Government both requires a notice of infringement or potential infringement as well as retention of economic liability for patent infringements. Specifically, in FAR §52.227.3 (a), the “Contractor shall indemnify the Government and its officers, agents, and employees against liability, including costs for infringement of any United States Patent…”. In addition to the patents cited by the USPTO in their examination of ‘600, M·CAM has identified fourteen other issued patents preceding the ‘600 patent which were used by patent examiners to limit patents arising from the same funded research including patents sought by CureVac.
In short, while Moderna enjoys hundreds of millions of dollars of funding allegiance and advocacy from Anthony Fauci and his NIAID, since its inception, it has been engaged in illegal patent activity and demonstrated contempt for U.S. Patent law. To make matters worse, the U.S. Government has given it financial backing in the face of undisclosed infringement risks potentially contributing to the very infringement for which they are indemnified.
Modrena’s U.S. Patent 10,702,600 and U.S. Patent 10,702,599 share reference to this language:
Severe acute respiratory syndrome (SARS) emerged in China in 2002 and spread to other countries before brought under control. Because of a concern for reemergence or a deliberate release of the SARS coronavirus, vaccine development was initiated (emphasis added).
http://patft.uspto.gov/netacgi/nph-Parser? Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1 &f=G&l=50&s1=10702600.PN.&OS=PN/10702600&RS=PN/10702600
March 2019 reference to the “deliberate release” of SARS: Application 16/368,270 and these four other applications:
2019024031 7 HPIV3 RNA VACCINES
2019021691 7 HMPV RNA VACCINES
2018032604 5 COMBINATION PIV3/HMPV RNA VACCINES
2017034072 5 COMBINATION PIV3/HMPV RNA VACCINES
On March 28, 2019 (9 months before the SARS outbreak), Moderna altered a rejected patent application in which they stated that vaccine development for SARS coronavirus was initiated based on concern for a “deliberate release of SARS coronavirus”. Since 2010, Moderna has known that other companies own the patent on lipid nanoparticles (LNP) required to deliver the vaccine. Given Moderna’s over 130 cases of violating the law in their patent filing and given their executives’ stock sales, there is reason to be concerned that Dr. Anthony Fauci is setting up President Trump for a patent infringement injunction on the eve of the vaccine approval. Dr. Fauci has been promoting a vaccine that clearly violates the Federal Acquisition Regulations and he’s likely known it since the company’s IPO in 2018.
Ralph Baric – Gilead Remdesivir
Richard Whitely – Gilead Remdesivir Moleculin https://ir.moleculin.com/press-releases/detail/167/ moleculin-announces-head-of-niaid-antiviral-drug-discovery
Shaman https://www.sfgate.com/business/article/Shaman Pharmaceuticals-antiviral-drug-scores-well-3124769.php